Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection
HE Cui-Yao1, QIN Yan-Ran2, LIU Cheng-Jun2, REN Jie3, FAN Ji-Shan1
Department of Pharmacy, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders(Chongqing)/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
Abstract Objective To investigate the effect of augmented renal clearance (ARC) on plasma concentration of vancomycin, bacteriological outcome, and clinical outcome in children with methicillin-resistant Staphylococcus aureus (MRSA) infection treated by vancomycin. Methods A retrospective analysis was performed for the clinical data of 60 critically ill children who were treated with vancomycin due to MRSA infection from January 2013 to July 2017 and underwent plasma concentration monitoring. According to estimated glomerular filtration rate, these children were divided into an ARC group with 19 children and a normal renal function group with 41 children. The two groups were compared in terms of the use of vancomycin, plasma concentration of vancomycin, and treatment outcome. Results The children in the ARC group had an age of 1-12 years, and the ARC group had significantly higher body weight and body surface area than the normal renal function group (P P P > 0.05), but the ARC group had significantly longer length of stay in the pediatric intensive care unit (PICU) and length of hospital stay than the normal renal function group (P Conclusions ARC can significantly reduce the trough concentration of vancomycin and prolong the length of PICU stay and the length of hospital stay in children with MRSA infection. Idividualized medication should be administered to children with ARC.
HE Cui-Yao,QIN Yan-Ran,LIU Cheng-Jun et al. Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection[J]. CJCP, 2019, 21(9): 904-909.
HE Cui-Yao,QIN Yan-Ran,LIU Cheng-Jun et al. Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection[J]. CJCP, 2019, 21(9): 904-909.
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Am J Health Syst Pharm, 2009, 66(1):82-98.
Huttner A, Von Dach E, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill:an observational prospective cohort study[J]. Int J Antimicrob Agents, 2015, 45(4):385-392.
[7]
Claus BO, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy[J]. J Crit Care, 2013, 28(5):695-700.
[8]
De Cock PA, Standing JF, Barker CI, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children[J]. Antimicrob Agents Chemother, 2015, 59(11):7027-7035.
[9]
Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance[J]. Ther Drug Monit, 2016, 38(3):393-397.
[10]
Avedissian SN, Bradley E, Zhang D, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients[J]. Pediatr Crit Care Med, 2017, 18(9):e388-e394.
Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU:results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations[J]. Crit Care Med, 2014, 42(3):520-527.
[15]
Campassi ML, Gonzalez MC, Masevicius FD, et al. Augmented renal clearance in critically ill patients:incidence, associated factors and effects on vancomycin treatment[J]. Rev Bras Ter Intensiva, 2014, 26(1):13-20.
[16]
Baptista JP, Roberts JA, Sousa E, et al. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients:developing and testing of a dosing nomogram[J]. Crit Care, 2014, 18(6):654.
[17]
Baptista JP, Sousa E, Martins PJ, et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation[J]. Int J Antimicrob Agents, 2012, 39(5):420-423.
[18]
Barriere SL, Stryjewski ME, Corey GR, et al. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus:a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies[J]. BMC Infect Dis, 2014, 14:183.
[19]
McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus bacteremia in children:evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome[J]. Pediatr Infect Dis J, 2016, 35(3):263-268.
[20]
Men P, Li HB, Zhai SD, et al. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness:a systematic review and meta-analysis[J]. PLoS One, 2016, 11(1):e0146224.
